TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31219558
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch for 24 weeks
Study: 15553595
Drug: Prostaglandin E1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin E1, 40 microg infused twice daily for 28 days (group A)
Study: 8446852
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) therapy for 6 to 24 months
Study: 28985263
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg daily for 15 weeks
Study: 20502296
Drug: Foley balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley balloon inflated to 30 mL
Study: 20502296
Drug: Foley balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley balloon inflated to 60 mL
Study: 17823963
Drug: Caffeine-free solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-free solution (control)
Study: 12471278
Drug: Droperidol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (20 mg/kg)
Study: 2254769
Drug: Self-administered diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered diet history questionnaire
Study: 140786
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide lotion
Study: 140786
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A acid cream
Study: 29112488
Drug: RIBSP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIBSP vaccine
Study: 29112488
Drug: VAXIGRIP® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAXIGRIP® vaccine
Study: 30442437
Drug: l-carnitine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine administration (1000mg of oral liquid l-carnitine once daily for 8 weeks)
Study: 30442437
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no l-carnitine administration)
Study: 30442437
Drug: l-carnitine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine administration
Study: 27598802
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months initial chemotherapy (CT)
Study: 27598802
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months initial chemotherapy (CT)
Study: 27598802
Drug: No initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No initial chemotherapy (CT)
Study: 11926556
Drug: Lanreotide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide 0.5 mg
Study: 9790077
Drug: Polyacrylonitrile (AN69)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyacrylonitrile (AN69) membrane plus subcutaneous EPO after HD
Study: 9790077
Drug: Cuprophan membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuprophan membrane plus subcutaneous EPO after HD
Study: 9790077
Drug: AN69 membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN69 membrane plus subcutaneous EPO after HD plus intravenous EPO immediately before HD
Study: 9790077
Drug: Cuprophan membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuprophan membrane plus subcutaneous EPO after HD plus intravenous EPO immediately before HD
Study: 2116156
Drug: infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion of propofol
Study: 28074795
Drug: Grape Seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape Seed Extract (GSE) 100 mg every 6 hours orally, 24 hours before operation
Study: 28074795
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 25 mg/kg through CPB during surgery
Study: 9688727
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of estrogen and progesterone therapy
Study: 9688727
Drug: No hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormone replacement therapy (No HRT)
Study: 1681781
Drug: naltrexone hydrochloride
Normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naltrexone hydrochloride (50 mg/day)
Study: 1681781
Drug: propoxyphene hydrochloride
Normalized name: Propoxyphene Hydrochloride
DrugBank: Dextropropoxyphene (DB00647)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propoxyphene hydrochloride (260 mg/day)
Study: 31005396
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of intravenous ketorolac plus oxygen at 15 l/min through a non‐rebreather mask (NRB)
Study: 31005396
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of intravenous ketorolac plus 7 l/min of oxygen through a 60% venturi mask
Study: 31005396
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of intravenous ketorolac plus 4 l/min of oxygen through a nasal cannula
Study: 31005396
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of intravenous ketorolac and room air
Study: 24378381
Drug: Symax™ implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symax™ implant
Study: 21604858
Drug: Institutional adjunctive
Normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Institutional adjunctive instruction condition
Study: 21604858
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (no institutional adjunctive instruction)
Study: 18703936
Drug: Quetiapine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine plus fluoxetine
Study: 15714986
Drug: 5-alpha reductase
Normalized name: 5-alpha reductase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-alpha reductase inhibitor
Study: 12595861
Drug: Abciximab (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abciximab (0.125 mg/kg) administered twice at 10-minute intervals with UFH (70 U/kg)
Study: 12595861
Drug: Abciximab (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abciximab (0.125 mg/kg) administered twice at 10-minute intervals with dalteparin (60 IU/kg)
Study: 12595861
Drug: Receptor occupancy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receptor occupancy assay and PAC1 binding assay
Study: 1586385
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg erythromycin acistrate enteric coated tablets b.i.d. for 4 days after overnight fast
Study: 1586385
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg erythromycin acistrate enteric coated tablets b.i.d. for 4 days after a light breakfast
Study: 1586385
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg erythromycin acistrate enteric coated tablets b.i.d. for 4 days after a heavy breakfast
Study: 1586385
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg erythromycin acistrate enteric coated tablets b.i.d. for 4 days (steady state)
Study: 3702224
Drug: 0.55 to
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.55 to 0.60 g protein/kg/day
Study: 27680597
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of gabapentin and oxybutynin
Study: 22682768
Drug: Mifepristone-misoprostol (n=220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone-misoprostol (n=220) - 200mg mifepristone on day 1 and 800 μg buccal misoprostol followed by placebo 3 hours later on day 2
Study: 22682768
Drug: Misoprostol-only (n=221)
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol-only (n=221) - placebo on day 1 and 1600 μg of misoprostol (2 doses of 800 μg, given 3 hours apart) on day 2
Study: 16213288
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) plus 1 g/d Mycophenolate mofetil (MMF)
Study: 16213288
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) plus 2 g/d Mycophenolate mofetil (MMF)
Study: 12236848
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort extract (255-285 mg, 900 micro g hypericin content)
Study: 6781808
Drug: Methadone 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 15 mg . HCl
Study: 27405619
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate (LC) 750 mg/day, titrated up to 2250 mg/day
Study: 27405619
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CC) 3 g/day, titrated to achieve serum P levels of 3.5-6.0 mg/dL
Study: 21359925
Drug: No acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: No acupuncture treatment (Group C)
Study: 19699111
Drug: Clofazimine 100
Normalized name: clofazimine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofazimine 100 mg daily for 30 days, then 100 mg every other day
Study: 19699111
Drug: Colchicine 0.5
Normalized name: colchicine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.5 mg 3 times daily
Study: 19699111
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 pill 2 times daily
Study: 7799341
Drug: D-penicillamine (intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine (intermittent treatment, every Monday, Wednesday, and Friday)
Study: 7799341
Drug: D-penicillamine (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine (daily treatment)
Study: 7799341
Drug: Both daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both daily and intermittent D-penicillamine treatments
Study: 31454502
Drug: Lidocaine (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.8 mL, 36 mg lidocaine HCl and 0.0225 mg epinephrine)
Study: 31454502
Drug: Tramadol (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (1.8 mL, 50 mg tramadol HCl and 0.0225 mg epinephrine diluted to 1.8 mL by distilled water)
Study: 25072444
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy (adefovir 10 mg/d)
Study: 23632053
Drug: PIL approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIL approach (80 mg methylprednisolone)
Study: 23632053
Drug: MIL approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIL approach (80 mg methylprednisolone)
Study: 16174713
Drug: Kisspeptin-54 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kisspeptin-54 infusion (4 pmol/kg x min)
Study: 8324915
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (0.9%)
Study: 8902860
Drug: Nebulized terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized terbutaline (2 ml solution diluted with 2 ml 0.9% saline for inhalation over 10 minutes)
Study: 8902860
Drug: Injected epinephrine
Normalized name: epinephrine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected epinephrine (0.01 ml/kg of 1:1000 epinephrine, maximum 0.3 ml, subcutaneous injection)
Study: 1867917
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with 400 mg cimetidine
Study: 1867917
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy with cimetidine
Study: 30633334
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance training (PRT) 3 times per week for 50 weeks (20 weeks supervised, 30 weeks self-administered)
Study: 15018291
Drug: Fludrocortisone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (0.3 mg orally 7 hours prior to landing)
Study: 9716055
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (fourth course of FE120C, followed by radiation therapy and 2 years of tamoxifen)
Study: 9716055
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (identical treatment but with an additional high-dose regimen and peripheral-blood progenitor-cell support after the fourth FE120C course)
Study: 7984328
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon beta
Study: 2721109
Drug: 337.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 337.5 mg/day propafenone
Study: 2721109
Drug: 450 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg/day propafenone
Study: 2721109
Drug: 675 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 675 mg/day propafenone
Study: 2721109
Drug: 900 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg/day propafenone
Study: 127471
Drug: Ro 6-0787
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 6-0787 combined with penicillin therapy
Study: 127471
Drug: Combined Ro
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Ro 6-0787-penicillin treatment
Study: 25923852
Drug: d-cycloserine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-cycloserine (50 mg daily)
Study: 25923852
Drug: d-cycloserine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-cycloserine (50 mg weekly)
Study: 21305238
Drug: Back school
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Back school + exercise + physical treatment modalities
Study: 21305238
Drug: Exercise +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise + physical treatment modalities
Study: 21167689
Drug: Enriched supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched supportive therapy (EST)
Study: 27684809
Drug: Glucose 75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 75% solution
Study: 24158271
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation (DBS) combined with best medical therapy (BMT)
Study: 17210383
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical therapy (BMT) alone
Study: 16291717
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive (ethinyl estradiol 35 microg and varying doses of norgestimate: 0.18, 0.215, and 0.25 mg)
Study: 16291717
Drug: No triphasic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No triphasic oral contraceptive (control)
Study: 11896479
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg phentolamine + 6 mg apomorphine
Study: 11896479
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg phentolamine + 150 mg papaverine
Study: 11896479
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg phentolamine + 6 mg apomorphine + 150 mg papaverine
Study: 7650334
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha therapy (360‐700 MU/square meter of body surface, 2 or 3 times weekly for 12 to 24 weeks)
Study: 2516669
Drug: R/5 (rifampicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: R/5 (rifampicin, streptomycin, isoniazid, and pyrazinamide daily for 2 months, followed by streptomycin, isoniazid, and pyrazinamide twice weekly for 3 months)
Study: 2516669
Drug: R/7 (rifampicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: R/7 (rifampicin, streptomycin, isoniazid, and pyrazinamide daily for 2 months, followed by streptomycin, isoniazid, and pyrazinamide twice weekly for 5 months)
Study: 2516669
Drug: Initial drug
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial drug resistance to streptomycin or isoniazid or both
Study: 5023913
Drug: Sterile fusidic
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile fusidic acid gel introduced into the cavity on one occasion only
Study: 5023913
Drug: Daily superficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily superficial dressings impregnated with sodium fusidate ointment
Study: 31858912
Drug: NSAIDs (Naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (Naproxen 1 gm/day or Etoricoxib 120 mg/day)
Study: 30639273
Drug: Sequential combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combination training (SEQ)
Study: 28459931
Drug: Daily calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily calorie restriction (75% of energy needs every day)
Study: 28459931
Drug: Daily calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily calorie restriction
Study: 21716078
Drug: non-HBV-active drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-HBV-active drugs
Study: 17171204
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg of elemental iron weekly for 6 months (anemic children)
Study: 17171204
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg of elemental iron weekly for 6 months (both treated groups)
Study: 1582642
Drug: Phytogenic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytogenic preparation
Study: 1582642
Drug: Ointment containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment containing synthetic substances
Study: 1582642
Drug: Ointment containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment containing synthetic substances with corticoid
Study: 3987543
Drug: Felodipine (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (0.25, 0.75, 1.5 mg)
Study: 3987543
Drug: Verapamil (2.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (2.0, 4.0, 8.0 mg)
Study: 3987543
Drug: Metoprolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (15 mg) after felodipine and verapamil
Study: 29284287
Drug: rAd-p53 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rAd-p53 therapy combined with radiotherapy and hyperthermia (p53 group)
Study: 25343963
Drug: Oral loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral loading dose of Vitamin D (500,000 IU) followed by an oral dose of 50,000 IU of Vitamin D monthly for 2 years
Study: 25343963
Drug: Oral high‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral high‐dose vitamin D therapy
Study: 23756453
Drug: Standard Fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Fluid Therapy (Control)
Study: 15982505
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg co-administered with simvastatin 10 mg or 20 mg
Study: 15982505
Drug: Placebo co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo co-administered with simvastatin 10 mg or 20 mg
Study: 12626793
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural intervention (8-week adjunctive psychological intervention)
Study: 11097197
Drug: Cocaine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (80 mg/70 kg p.o.)
Study: 9206191
Drug: Mifepristone 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 150 mg in separated doses followed by PG05 1 mg vaginally
Study: 9206191
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg in single dose followed by PG05 1 mg vaginally
Study: 29125679
Drug: Topical Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Tranexamic Acid (TXA) 500 mg in 5 mL
Study: 28471579
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy plus pharmacological treatment for 21 days
Study: 22533654
Drug: AZL‐M 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL‐M 40 mg and CLD 25 mg
Study: 22533654
Drug: AZL‐M 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL‐M 80 mg
Study: 22533654
Drug: CLD 25
Normalized name: CldAdo
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CLD 25 mg
Study: 16109117
Drug: Divalproex 500
Normalized name: DIVALPROEX 500MG 24HR (ER) SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divalproex 500 mg/day
Study: 16109117
Drug: Divalproex 1000
Normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex 1000 mg/day
Study: 16109117
Drug: Divalproex 1500
Normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex 1500 mg/day
Study: 12145720
Drug: Levofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (750 mg once per day)
Study: 12145720
Drug: Ticarcillin-clavulanate (3.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticarcillin-clavulanate (3.1 g iv every 4-6 hours) followed by amoxicillin-clavulanate (875 mg orally every 12 hours)
Study: 11026121
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance treatment (MMP) with adjunctive manual-guided psychosocial group interventions
Study: 11026121
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance treatment (MMP)
Study: 8477058
Drug: Regimen S1
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen S1 (cranial irradiation 18 Gy and intrathecal chemotherapy starting at 5 weeks)
Study: 8477058
Drug: Regimen S2
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen S2 (cranial irradiation and intrathecal chemotherapy starting at 24 weeks)
Study: 23192720
Drug: Compelled body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compelled body weight shift (CBWS) therapy combined with physical therapy